Keio University · Faculty of Pharmaceutical Sciences / Graduate School of Pharmaceutical Sciences

Research keywordsDDX5・JAK2V617F・myeloproliferative neoplasms・Nrf2 activation・mTOR signaling・STAT3 phosphorylation

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• KMN003 activates Nrf2 via disruption of the Keap1-Nrf2 interaction and p38-dependent transcriptional regulation2026 · Cellular Signalling 137 2026年01月
• DDX5 is required for JAK2V617F-induced cell proliferation and tumorigenesis independent of its RNA helicase activity2026 · Cellular Signalling 138 2026年02月
• Targeting DDX5 using FL118 suppresses mTOR signaling and tumorigenicity in JAK2V617F-driven myeloproliferative neoplasms2026 · International Immunopharmacology 173 2026年03月
• TRPV1 attenuates epithelial-mesenchymal transition via calpain-protein tyrosine phosphatase pathway in lens epithelial cells2025 · Experimental Eye Research 258 2025年09月

• STAT3標的遺伝子を介した未分化大細胞リンパ腫の発症機序の解明2023 · -
• エリスロポエチン受容体結合分子を介した慢性骨髄増殖性腫瘍の発症機序の解明2020 · -
• エリスロポエチン受容体のリン酸化を介した慢性骨髄増殖性腫瘍の発症機序の解明2017 · -

• Official profile